₹35 per tablet in India.The stocks of FluGuard will be available in the market from this week, Sun Pharma said in a regulatory filing.Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate COVID-19 disease, Sun Pharma added.
Other Indian drugmakers developing or selling favipiravir include Glenmark Pharmaceuticals, Hetero and Cipla.Click here to read the Mint ePaperLivemint.com is now on Telegram.